A Pivotal Phase III Study Of MIN-101 In Schizophrenic Patients With Negative Symptoms

Trial Profile

A Pivotal Phase III Study Of MIN-101 In Schizophrenic Patients With Negative Symptoms

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs MIN 101 (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Minerva Neurosciences
  • Most Recent Events

    • 03 Aug 2017 According to a Minerva Neurosciences media release, the company expect to release top-line results from the three-month double blind phase of the trial in the first half of 2019.
    • 22 Jun 2017 According to a Minerva Neurosciences media release, company announced successful completion of a bridging trial (MIN101C06) to select an improved, gastric-resistant (GR) formulation of MIN-101 for this phase III study.
    • 15 May 2017 According to a Minerva Neurosciences media release, the company announced the outcome of its End-of-Phase 2 meeting with FDA which includes its plans to initiate phase 3 development of MIN-101.This meeting helped the company to confirm this phase 3 trial design.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top